Novartis India Limited has submitted its quarterly compliance certificate to BSE Limited under SEBI regulatory requirements for the quarter and financial year ended March 31, 2026. The pharmaceutical company filed the mandatory certificate as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the Registrar to an Issue and Share Transfer Agent for Novartis India Limited. The document was dated April 06, 2026, and subsequently filed with the stock exchange on April 13, 2026.

Certificate Confirmation

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialization during the quarter ended March 31, 2026, were properly processed within prescribed timelines. The registrar verified that security certificates received for dematerialization were confirmed or rejected appropriately, and that certificates were mutilated and cancelled after due verification by the depository participant.

The certificate also confirmed that the names of depositories were substituted in the register of members as registered owners within the prescribed timelines. Notably, the registrar reported that no requests for rematerialization were received during the quarter.

Corporate Information

Novartis India Limited operates from Inspire BKC, 7th Floor, Bandra Kurla Complex, Bandra East, Mumbai. The company's securities are listed on BSE Limited under scrip code 500672. The compliance certificate was signed by Chandni Maru, Company Secretary and Compliance Officer, demonstrating the company's commitment to maintaining proper regulatory adherence.

This routine filing reflects the company's ongoing compliance with SEBI regulations governing depositories and participants, ensuring transparent and proper handling of securities transactions during the reporting period.

Novartis AG, the Swiss pharmaceutical major and promoter of Novartis India Limited, has filed a mandatory regulatory disclosure with BSE Limited confirming that no lien has been created on its equity holdings and reiterating details of its previously announced divestment agreement.

Lien Declaration on Equity Holdings

In compliance with Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, Novartis AG declared that it has not created any lien on its 1.74 crore equity shares in Novartis India Limited, either directly or indirectly, as of March 31, 2026.

Sale Agreement Confirmation

The disclosure reaffirmed the sale and purchase agreement (SPA) entered into on February 19, 2026, for the complete divestment of Novartis AG's stake in its Indian subsidiary. The transaction involves three strategic acquirers who will collectively acquire the entire promoter holding.

Acquirer Details

The sale agreement encompasses three distinct entities:

• WaveRise Investments Limited (Acquirer 1)
• ChrysCapital Fund X (Acquirer 2)
• Two Infinity Partners (Acquirer 3)

Regulatory Compliance

The filing demonstrates Novartis AG's adherence to Indian securities regulations governing substantial shareholding transactions. The disclosure was addressed to BSE Limited and copied to the Audit Committee of Novartis India Limited, ensuring comprehensive regulatory notification.

The document was signed by authorized signatories Lukas Förtsch and Stefan Thommen, representing Novartis AG's commitment to maintaining transparency throughout the divestment process. This regulatory filing provides stakeholders with updated information on the transaction's progress and confirms the integrity of the shareholding structure pending completion of the sale.